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Cytomegalovirus viral load within blood
increases markedly in healthy people over
the age of 70 years
Helen M. Parry1*, Jianmin Zuo1, Guido Frumento1, Nikhil Mirajkar2, Charlotte Inman1, Emma Edwards1,5,
Mike Griffiths3, Guy Pratt1 and Paul Moss1,4
Abstract
Background: Cytomegalovirus (CMV) is a highly prevalent herpesvirus, which maintains lifelong latency and places a
significant burden on host immunity. Infection is associated with increased rates of vascular disease and overall mortality
in the elderly and there is an urgent need for improved understanding of the viral-host balance during ageing.
CMV is extremely difficult to detect in healthy donors, however, using droplet digital PCR of DNA from peripheral blood
monocytes, we obtained an absolute quantification of viral load in 44 healthy donors across a range of ages.
Results: Viral DNA was detected in 24 % (9/37) of donors below the age of 70 but was found in all individuals above
this age. Furthermore, the mean CMV load was only 8.6 copies per 10,000 monocytes until approximately 70 years of
age when it increased by almost 30 fold to 249 copies in older individuals (p < 0.0001). CMV was found within classical
CD14+ monocytes and was not detectable within the CD14-CD16+ subset. The titre of CMV-specific IgG increased
inexorably with age indicating that loss of humoral immunity is not a determinant of the increased viral load. In contrast,
although cellular immunity to the structural late protein pp65 increased with age, the T cell response to the immediate
early protein IE1 decreased in older donors.
Conclusion: These data reveal that effective control of CMV is impaired during healthy ageing, most probably due to loss
of cellular control of early viral reactivation. This information will be of value in guiding efforts to reduce CMV-associated
health complications in the elderly.
Keywords: Cytomegalovirus, Ageing, Monocyte, ddPCR, Lifespan
Background
Cytomegalovirus (CMV) is one of eight human herpesvi-
ruses and maintains a state of lifelong latency within the
host following primary infection. CMV is highly prevalent
in all parts of the world and infection rates increase with
age, with seropositivity estimated between 50 and 95 % in
those aged over 5 years [1, 2]. Viral replication is con-
trolled by the development of a strong cellular and
humoral CMV-specific immune response and this must
be maintained throughout life in order to prevent episodes
of clinically significant viral reactivation [3]. The magni-
tude of the CMV-specific immune response within the
blood is very large and higher than has been recorded
against other pathogens [4, 5]. Moreover this immune
response increases further with age in a phenomenon that
has been termed ‘memory inflation’ [6]. This is associated
with reduction in the CD4:8 ratio and accumulation of
large numbers of late-differentiated memory cells [7].
However, there is now concern that CMV infection can
serve to accelerate the development of immune senes-
cence and several studies have shown that CMV seroposi-
tivity is associated with a range of clinical problems and
increased risk of mortality in older people [8–12].
Although CMV rarely leads to overt clinical problems
after primary infection, it is believed that subclinical epi-
sodes of CMV reactivation occur frequently during a
lifetime but are rapidly controlled by the host immune
response [13]. In order to understand more about the
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mechanisms by which CMV infection may impact on
the health of elderly donors it is important to improve
understanding of the level of CMV load within the blood
and how this is related to specific features of the CMV-
specific immune response. This information might then
potentially be used to determine the optimal ‘set point’
of viral-host balance and as such serve as an aspiration
to achieve within future interventional therapy, for in-
stance with anti-viral or immune modulatory treatment.
The sites of CMV latency include haemopoietic stem
cells, monocytes and epithelial cells. However the level
of CMV within the blood is very low and conventional
PCR assays are almost invariably negative in healthy
donors [14–17]. Indeed this is a useful clinical finding,
as a positive CMV PCR is generally interpreted as
evidence of clinically significant reactivation in immune
suppressed donors and can be used to guide anti-viral
therapy. However, purification of discrete cell subsets that
harbor viral infection, followed by PCR amplification, is
one approach that can be taken to increase the sensitivity
of viral detection [18]. Self-renewing CD34+ haemopoietic
stem cells represent a reservoir for maintaining viral infec-
tion and it has been estimated that latent virus is present
in 0.01–0.001 % of myeloid progenitor cells within bone
marrow [15, 19, 20]. Monocytes are the major mature
haemopoietic cellular host for CMV carriage and the fre-
quency of infected cells is thought to be approximately 10
fold lower [21, 22]. Viral latency is maintained during
monocytic carriage, whereas lytic viral replication can only
arise following differentiation of monocytes into macro-
phages, due to changes in the pattern of chromatin bind-
ing to the immediate early promoter [23–25].
The use of highly sensitive PCR assays increases the fre-
quency of CMV detection and nested PCR offers the ad-
vantage of substantial sensitivity but is poorly quantitative.
Droplet digital PCR (ddPCR) is a new approach that pro-
vides a highly sensitive and direct method for detection of
target DNA without the need for developing a ‘standard
curve’. ddPCR emulsifies an oil-based PCR reaction into
thousands of droplets, each of which then acts as a PCR
micro-reaction and increases the chances of a rare event
being detected. Using Poisson’s distribution, a direct
measurement of the target DNA can then be determined.
ddPCR does not therefore rely on any interpretation of
rate-based data, as is the case with Q-PCR. The sensitivity
and versatility of ddPCR for detection of low copy number
events has been shown in several settings and is increas-
ingly part of clinical practice for monitoring mutations
levels in malignant disease [26, 27].
We have utilized purification of monocytes combined
with droplet digital PCR to permit accurate quantification
of the level of CMV within the blood of healthy donors.
Our data showed that this provides a highly informative
technique to quantify CMV viral load. Moreover they
revealed that virus is found infrequently within the blood
until the age of around 70 years when it becomes detect-
able in every donor. We showed that virus is present exclu-
sively within the ‘classical’ CD14+ monocyte fraction and
that the increase in viral load correlated with a decrease in
the cellular immune response to immediate early protein.
These findings have important implications for under-
standing the biology and clinical complications of CMV
infection.
Results
Droplet digital PCR can be used for detection of CMV
within the monocytes of healthy donors
Blood samples were obtained from 44 healthy donors
between 25 and 86 years of age. CD14+ monocytes were
purified by positive selection using magnetic beads and
then DNA was extracted using miniprep kits. CMV-
specific PCR primers and droplet digital PCR analysis
(ddPCR) was then used to determine the number and
proportion of CMV-positive droplets within each sam-
ple. Positive droplets were defined as those detectable
above the set threshold (Fig. 1a) and Poisson’s distribu-
tion was used to determine the absolute copy number of
the reaction. Using this approach, CMV was detected in
16 of the 44 donors (36 %) and was confirmed in each
case by 3 independent runs.
CMV viral load within monocytes increases markedly
above the age of 70 years
When the results were assessed in relation to donor age
it was clear that the proportion of donors in whom
CMV was detectable increased markedly with age. Spe-
cifically, CMV was detected in 9 of 37 (24 %) of donors
aged below 70 years whereas a positive test was seen in
each of the 7 donors above this age (Fig. 1b). In those
aged 20–30 years, only 1 out of 6 donors (16.7 %) had a
detectable load, compared to 1 out of 4 (25 %) in 30–40
year olds, 1 out of 13 (7.7 %) in 40–50 year olds, 3 out
of 8 (37.5 %) in 50–60 year olds and 3 out of 6 (50 %) in
60–70 year olds.
The absolute quantification of CMV viral load in rela-
tion to monocyte number was then determined by
QuantaSoft® software in order to generate a value of
‘viral load per 10,000 monocytes’. In those donors in
whom CMV was detectable by ddPCR, the absolute viral
load varied markedly from 3 copies per 10,000 mono-
cytes to 353 copies per 10,000 monocytes, a range of
117 fold. This value was also found to increase with age,
again with a marked increase observed in donors aged
over 70 years (kruskal-wallis p = 0.0005). The mean viral
load in donors aged below 70 years was 8.6 copies per
10,000 monocytes (SD 38), with a 29-fold increase in
those over the age of 70, where the mean viral load was
249 copies per 10,000 monocytes (SD 59) (Fig. 1c).
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Modelling of the data with an exponential growth curve
showed that the CMV viral load doubling time was
9.6 years (R2 = 0.64) (Fig. 1d).
The increase in CMV viral load with age is confirmed
through the use of quantitative PCR
We next used a second method in order to confirm the
observation of an increase in CMV load within monocytes
in relation to age. Quantitative PCR (Q-PCR) was applied
to the same sample cohort using an average plasmid series
dilution, which produced an R2 value of 0.983 (p < 0.0001)
(Additional file 1: Figure S1A). Using triplicate runs, Q-
PCR was sensitive down to a single copy of plasmid CMV
per reaction. This same series of diluted plasmids was then
verified using ddPCR and the absolute copy number of
CMV was calculated through QuantaSoft® software.
ddPCR was again capable of detecting 1 copy of CMV per
reaction indicating that results generated from ddPCR and
Q-PCR correlated very strongly (R2 = 0.995; p = <0.0001)
(Additional file 1: Figure S1B).
We then used Q-PCR to assess CMV load within the 44
samples of monocyte DNA from healthy donors. Thirteen
of the 16 samples that were found to be positive by digital
PCR were also detected as positive by Q-PCR (81 %).
Twenty-seven out of the 28 samples that were negative by
ddPCR were also negative by Q-PCR and only one was re-
ported positive by Q-PCR. The correlation between the
two techniques using 13 results that were positive by both
methods had a co-efficient of determination of R2 = 0.626
(p = 0.0013). The Q-PCR technique also revealed a pro-
nounced increase in viral load in association with age
(Additional file 1: Figure S1C).
CMV viral load is detectable within CD34+ haemopoietic
cells and is focused within ‘classical’ CD14+ monocytes
In order to determine the distribution of CMV load
within different cells of the myeloid lineage we then
went on to perform ddPCR on purified CD34+ haemopoi-
etic stem cells and individual monocyte subsets. CD14 and
CD16 expression can be used to subdivide the major
subpopulations of monocytes into CD14 + CD16-, CD14 +
CD16+ and CD14-CD16+ subsets (Fig. 2a). Fractions of
G-CSF-mobilised peripheral blood were obtained from five
haemopoietic stem cell donors and cells were sorted into
CD34+ stem cells and monocytic subsets (Fig. 2b). CMV
was detected in 3 of these 5 samples through the use of
both ddPCR and Q-PCR. Interestingly, within the
monocyte subsets, CMV was found only within classical
monocytes with a CD14+ phenotype whereas the CD14-
CD16+ subset was entirely negative by both assays (Fig. 2c).
Fig. 1 CMV viral load in monocytes increases with ageing. CMV viral load within monocytes increases markedly above the age of 70 years. The DNA of
purified CD14+ monocytes was extracted and CMV virus load was detected using droplet digital PCR analysis (ddPCR). a Positive droplets were defined
as those detectable above the set threshold as shown in healthy donor (HD) 1 and 3. HD 2 had no detectable CMV viral load. b The CMV virus load was
checked in 44 donors, aged between 20 and 90 years of age. The frequency of donors with detectable latent CMV viral load increases with age. c The
absolute viral load per 10,000 monocytes was determined by QuantaSoft® software using RRP30 as an internal control. The CMV viral load increases
dramatically over the age of 70. d The CMV virus load data was modelled with the exponential growth curve to show the CMV viral load doubling time
was 9.6 years
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The titre of the CMV-specific IgG response increases with
age
Our previous data showed an increase in CMV load within
the peripheral blood during healthy ageing, so we next
went on to determine the magnitude of the CMV-specific
immune response in association with age. In particular, we
assessed if the increase in viral load might result from a
reduction in the magnitude of virus-specific immunity or if
the immune response might actually increase as a response
to the increased level of virus in the blood. We therefore
determined the CMV-specific IgG titre using a quantitative
ELISA assay against viral lysate. Interestingly, antibody titre
increased substantially during ageing with a three fold
increase in titre between the ages of 20 and 80 years (mean
titre 65.1 in donors aged 20 years compared to 232 in those
aged over 70); r = 0.473; p = 0.001). This increase in titre
developed gradually during ageing and therefore had a
different pattern to the quite dramatic elevation in viral
load that was seen only after the age of 70 years (Fig. 3).
The CMV-specific T cell response to pp65 also increases
with age whereas recognition of IE-1 is reduced in elderly
donors
We next went on to assess the magnitude of the T cell
immune response against CMV within the study cohort.
Specifically, we focused on the cellular responses to pp65
and immediate early 1 (IE-1), which are two of the most
immunodominant components of the CMV proteome.
Several previous studies have reported the substantial
magnitude of the CMV-specific T cell immune response
within peripheral blood and have also identified that this
can increase further with age [28, 29].
T cells were stimulated with peptide pools containing
immunodominant epitopes from either pp65 or IE-1 and
the IFN-γ release by peptide-specific CD4 and CD8 T cells
was then determined by flow cytometry (Fig. 4a). The
magnitude of the pp65-specific CD8+ T cell immune
response ranged from 0 to 5.5 % of the CD8+ T cell pool,
with a median value of 0.28 %. This value was over two-
fold higher in those donors with detectable CMV viral
load within monocytes compared to donors in whom the
ddPCR was negative, but this did not reach statistical
significance (0.5 vs 0.23 % respectively; p = 0.087). The
pp65-specific T cell response also increased markedly with
Fig. 2 CMV viral load is detectable in CD14 positive monocytes.
CMV viral load is detectable within CD34+ haemopoietic cells
and is focused within ‘classical’ CD14+ monocytes. DNA from CD34+,
CD14 + CD16-, CD14 + CD16+ and CD14-CD16+ populations were
used to detect CMV viral load using ddPCR. a Representation of flow
plots used for selecting monocyte populations based on CD14+ and
CD16+ antibody staining. b Representation of flow plots used for
selecting CD34+ cells. c The frequency of detection of CMV viral
load was compared between the different subpopulations
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age, from a median value of 0.17 % in 20–30 year
olds to 1.17 % in those aged greater than 70 years
(r2 = 0.146, p = 0.03). A positive correlation with age was
also noted following pp65 stimulation of CD4+ T cells,
although this did not reach statistical significance.
In contrast to pp65, the frequency of CD8+ T cells rec-
ognizing IE-1 initially increased with age, but then peaked
in people aged 50–60 years and actually decreased in older
donors (median 0.01 % <50 years; 0.7 % 50–60 years and
0.1 % >70 years old; R2 = 0.05; p = 0.244). The CD4+ T cell
response to IE-1 peptide stimulation was of small magni-
tude but remained relatively constant across each age
group, with a median frequency of 0.01 % (Fig. 4b).
In summary, the magnitude of the cellular immune re-
sponse to the structural late protein pp65 increased with
age, whilst the CD8+ T cell response to IE-1 peaked at
the age of 50–60 years and reduced thereafter.
Discussion
Cytomegalovirus infection has been associated with a
variety of health problems in elderly people and there is
increasing interest in the mechanisms that underlie this
association. A key determinant in this regard will be
greater understanding of the balance of the viral load
and the host immune response during healthy ageing. In
this study we report, for the first time, that the level of
cytomegalovirus viral load within the blood increased
markedly in elderly people.
A novel feature of our work was the use of digital
droplet PCR to provide an accurate quantitative measure
of latent viral DNA. Previous methods for detection of
CMV from monocytic DNA generally relied on nested
PCR techniques, which made quantification challenging
and also raised substantial problems with reproducibility
[30]. Quantitative PCR is far more accurate but relies on
interpretation of the cycle threshold of a sample against
a known calibration standard. This is restricted by the
lower limit of detection of the standards and the rate of
amplification, which can vary between different PCR
Fig. 3 CMV igG titre increases with ageing. CMV-specific IgG antibody
titre increased substantially during ageing, with a three-fold increase in
titre between the ages of 20 and 80 years
Fig. 4 The T cell response to the immunodominant CMV protein
pp65 increases with age. T cells were stimulated with peptide
pools containing either pp65 or IE-1 and the IFN-g release by
peptide-specific CD4 and CD8 T cells was then determined.
a Representation of the flow plots for IFN-g response to pp65 and IE-1
peptide stimulation. b Correlation of the T cell response to IE-1 peptides
against age demonstrated a peak in people aged 50–60 years followed
by a decreased response in older donors. The CD4+ T cell response to
IE-1 peptide was small but remained relatively constant across all ages.
c Both CD4 and CD8 T cell response to pp65 increase with ageing
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runs. In contrast, digital PCR provides an absolute quan-
tification and avoids these limitations. Our analysis in-
cluded a direct comparison of ddPCR and Q-PCR and,
as expected, we observed an extremely high concordance
between the two technologies. However ddPCR was
found to offer superior sensitivity and reliability of de-
tection. Seventeen samples were found to be positive by
either ddPCR or Q-PCR, 16 of these by ddPCR and 14
by Q-PCR.
Our work was performed using DNA isolated from
monocytes, which are established as the most important
haemopoietic site of viral latency [31, 32], and which in
murine infection also serve to disseminate viral infection
to distal sites such as salivary gland [33]. The first interest-
ing finding was the observation that CMV was detectable
in only a minority of donors, as 64 % of people remained
negative by ddPCR despite the presence of chronic infec-
tion as confirmed by CMV-specific IgG positivity. Indeed,
in younger people below the age of 50 years, the detection
of CMV load in the blood was uncommon, being observed
in only 13 % of donors tested. The lower limit of detection
provided by ddPCR in our assay was for a single copy of
virus within the total reaction volume (20 μl) and as such
a negative result indicated absent or extremely low levels
of virus. This low level carriage may reflect a lower intrin-
sic probability of viral reactivation in younger donors but
is perhaps more likely to reflect the consequence of effect-
ive immune surveillance of viral replication in younger
individuals.
The frequency of viral detection increased markedly
with each decade above the age of 50 years to 37.5 and
50 % and finally became positive in every donor who
was older than 70. Interestingly the amount of viral
DNA detected within the blood also increased substan-
tially with age with a 29 fold increase observed between
donors aged less than 70 and those over this age. The
use of nested PCR also detected viral DNA within the
majority of healthy elderly donors [18]. These data indi-
cate that a gradual impairment in the ability to control
CMV load within blood starts around the age of 50 years
and then deteriorates markedly beyond the age of 70.
Importantly, our work did not address the number of
CMV copies within individual monocytes, which has
previously been shown to vary between 2 and 13 copies
per cell [15]. Thus, it remains uncertain if ageing is asso-
ciated with an increase in the number of viral copies
within each infected monocyte or if there is an increase
in the proportion of infected cells.
We were also interested to use the sensitivity of ddPCR
to examine the presence of CMV within specific subsets
of the myelo-monocytic lineage. CD14 and CD16 can be
used to delineate three major subclasses of monocyte [34],
classical monocytes (CD14 + CD16-) which account for
>70 % of peripheral monocytes and are important for
innate immunity. These, together with intermediate
monocytes (CD14 + CD16+) have more phagocytic prop-
erties than their non-classical CD14-CD16++ counterparts
[35]. Our data suggested that CMV was not detectable
within CD14-CD16+ monocyte cells, a finding which is in
contrast to murine CMV, where CD16+ monocytes have
been shown to exhibit higher levels of CMV latency than
CD14+ cells [33].
We were also interested to compare levels of CMV
load within haemopoietic precursors of the terminally
differentiated monocytic lineage. As such we isolated
CD34+ haemopoietic stem cells from G-CSF mobilized
blood donations. CMV was detected in 3 of these 5
samples, which is comparable to a previous report of 8
positive samples out of 12 using an alternative PCR
methodology [15]. This suggests that viral DNA may
either pass selectively into cells that differentiate into the
monocytic lineage or that some degree of viral replica-
tion occurs during myelopoiesis in order to sustain viral
loads during the periods of cellular proliferation prior to
monocyte formation.
Importantly, the ddPCR assay detects the level of viral
DNA but does not assess the level of infectious virion.
CMV was not detected by ddPCR within plasma samples
taken from donors identified to have a positive mono-
cyte viral load (n = 10). This indicated that viral DNA
was retained within cells, with no evidence of produc-
tion of extracellular virus (data not shown).
The direct measurement of viral DNA is a critical
component in efforts to understand the balance of viral
load and host immune response during natural CMV in-
fection, an ambition that has been achieved so effectively
for the study of HIV using RNA load. However, it is also
important to correlate these values with assessment of
the immune response to the virus.
Figure 5 gives a schematic overview of the parallel
changes in immunity and viral load that arise following
CMV infection over a lifetime. We observed that the
humoral immune response to CMV increased steadily and
markedly during ageing. Total immunoglobulin levels are
known to fall with ageing and so our increase in CMV-
specific antibody might appear somewhat surprising, but
has in fact been reported previously [36, 37]. It is likely
that episodes of subclinical viral reactivation serve to
boost CMV-specific immunity and indeed this accumula-
tion of CMV-specific immune memory may suppress the
development of heterologous immune responses, which is
a likely contributing factor towards immune senescence.
Nevertheless these observations suggest that impairment
in humoral immunity is not a major contributory factor
towards the increase in viral load with ageing.
Studies have shown that the T cell immune response to
CMV increases markedly with age such that the virus-
specific CD8+ T cell response can come to dominate the
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CD8+ T cell repertoire in some donors [3, 38]. This profile
of ‘memory inflation’ is also seen in murine CMV infec-
tion and is believed to be driven by recognition of viral
peptides on non-haemopoietic cells. Relatively little is
known about the specific profile of CMV proteins that
drive CD8+ T cell expansion during ageing, although the
importance of structural proteins such as pp65 are well
documented [3, 29]. Indeed, the presence of CMV DNA
within monocytic cells has been correlated with increased
pp65-specific T cell immunity in elderly donors [18].
Our work also observed an expansion of pp65-specific T
cells in relation to ageing, with an 8.4 fold increase between
the youngest and most elderly donors and may reflect an
incremental accumulation to recurrent subclinical episodes
of viral reactivation. However, assessment of the T cell
recognition of peptides derived from the immediate early
protein IE-1 revealed an increase in middle aged individ-
uals, with reduced recognition in those of an advanced age.
This observation supports previous work, which has
reported no significant increase in the IE-1 specific im-
mune response with ageing [39].
It is currently unclear why IE-1 responses appear to
wane with age. An important factor may relate to the
frequency of T cell exposure to IE-derived epitopes, as
these are presented to T cells repeatedly during the early
period of viral replication and serve to elicit a cellular
immune response that can prevent the late stages of
viral infection before late viral proteins such as pp65 are
produced. As such IE-1-specific T cells are exposed to
very high levels of antigen stimulation and may be more
susceptible to functional exhaustion than those directed
against late-stage viral proteins such as pp65 [40]. How-
ever the explanation for the differing T cell responses to
IE-1 and pp65 with ageing remains unclear and will
require larger cross sectional and longitudinal study.
The concept that ageing leads to an alteration in the
balance between viral load and the host immune response
during chronic viral infection is supported by a variety of
clinical and immunological observations. Herpes zoster,
which represents reactivation of varicella zoster virus
(VZV), is more common in the elderly and VZV titres
increase with age, a pattern also reported for Epstein Barr
Virus [41, 42]. Finally, levels of the persistent and highly
prevalent Torque tenovirus are also known to increase
markedly with ageing [43].
Conclusion
In conclusion, these data reveal the delicate balance that
has evolved between chronic CMV infection and the
host immune response and indicate that this symbiosis
can break down during ageing, where an increase in
CMV viral load occurs as the attritional effects of
chronic surveillance and the impact of immune senes-
cence become more apparent. It is likely that increased
understanding of the clinical importance of chronic viral
infection on human health will become an important
health consideration in future years.
Methods
Healthy donors
Forty-four CMV positive healthy donors (confirmed by
CMV ELISA) were recruited for study between the ages of
25 and 86 (mean 50.5). Healthy individuals below the age
of 65 were recruited from The University of Birmingham,
whilst those over 65 were recruited as part of the ongoing
Birmingham 1000 elder’s cohort which recruits elderly
healthy donors from the local community. Following a
50 ml blood donation, plasma and PBMCs were ex-
tracted over a ficoll density gradient and stored at
−160 °C. PBMCs were used for functional T cell studies
Fig. 5 An overview of the parallel changes in viral load and immunity during the lifetime of an individual infected with Cytomegalovirus. Schematic
representation of the relative changes in the peripheral blood viral load as well as humoral and T cell immune response to CMV over the human
life-course. Primary infection is shown as occurring during childhood, the most common age of infection. CMV viral load and CMV-specific IgG antibody
titre increases during ageing. CD8 T cell responses to IE-1 peptides peaked in people aged 50–60 years and then decreased in older donors, while T cell
response to pp65 peptides increase with ageing
Parry et al. Immunity & Ageing  (2016) 13:1 Page 7 of 10
and monocyte extraction whilst plasma was used for
CMV ELISA testing.
Five peripheral blood stem cell donors who had received
G-CSF mobilization were also recruited and aliquots of
PBMC stored at −160 °C prior to defrosting and extrac-
tion of myeloid cell subsets.
Extraction of cell subsets: CD14, CD34 and CD16
Enrichment of CD14, CD16, CD34 and dual positive
CD14/16 cells from stem cell donations were sorted by
flow cytomety (MoFLow sorter, BDBiosciences, Oxford,
UK). Following defrosting, cells were washed in PBS and
labeled for 15 min at 4° with LIVE/DEAD Fixable red dead
cell stain kit (Life technologies, UK), PE anti-CD34
(BDBiosciences), anti-CD56 FITC (BDBiosciences), anti-
CD14 FITC (BDBiosciences) and anti-CD16 Pe-Cy7
(Biolegend, San Diego, USA), prior to a further wash and
sorting. For extraction of CD14 positive cells from healthy
donor PBMC, positive selection using CD14 magnetically
labeled beads was used and an average enrichment found
to be 98.73 % (SD 0.39) by flow cytometry (Miltenyi
Biotec, Surrey, UK). DNA extraction was then performed
on the enriched cell populations according to the protocol
for GenElute Mammalian Genomic DNA miniprep kit
(Sigma-Aldrich, St. Louis, MO USA) and DNA concentra-
tion and purity checked using the Nanodrop 2000
(Thermo Scientific, Waltham, MA, USA).
CMV plasmid controls for standard curve generation
Human CMV HHV5 kit for Q-PCR amplification of glyco-
protein B was purchased and used for all CMV PCR reac-
tions within this work (PrimerDesign, Southampton, UK).
Using the provided plasmid control, reconstituted aliquots
were stored at −20 °C. Plasmid dilutions were then pre-
pared fresh for Q-PCR to validate detection of the ddPCR
assay and were diluted to produce the following copies per
reaction: 50000, 10000, 2500, 500, 250, 100, 50, 10, 5 and 1.
Droplet digital PCR
Using the QX100 droplet digital PCR system (Bio-rad,
Pleasanton, CA), a reaction mixture consisting of 5ul of
either CD14 positive DNA (10 ng/ul) or plasmid standard
made up to a volume of 8ul with PCR grade water, 10ul of
2 × ddPCR supermix for probes (Bio-rad), 1ul of reconsti-
tuted FAM labeled CMV primer and probe (Primer
Design) and 1ul of HEX labeled RPP30 copy number assay
for ddPCR (Bio-Rad) were loaded into a disposable plastic
cartridge for droplet generation (Bio-Rad). Seventy micro-
litre of droplet generation oil (Bio-Rad) was also added
before loading the cartridge into the droplet generator
(Bio-Rad). After droplet generation, the sample was loaded
into a 96 well PCR plate (Eppendorf, Hamburg, Germany)
and PCR amplification carried out using the T100 thermo-
cycler (Bio-Rad). PCR conditions consisted of 10 min at
95 °C, prior to 40 cycles at 94 °C for 30 s and 60 s at 60 °C
and a finally 1 cycle at 10 min at 98 °C, ending at 12 °C.
After amplification the plate was loaded onto the droplet
reader (Bio-rad) and results analysed by QuantaSoft®
software (Bio-Rad) to give the number of virus copies per
ul of PCR reaction. A positive and negative control was
used in each experiment, which also verified the
consistency of droplet amplitude, and a well consisting
solely of water was also included. Results were obtained in
triplicate. As each mammalian cell contains 2 copies of
RPP30, the absolute quantification of RPP30 was divided
by two in order to determine the actual cell number. The
CMV viral load was then divided by this figure to obtain
the CMV load per cell.
Q-PCR
Using the 7500 Real Time PCR system (Applied
Biosystems, California, USA), a PCR reaction mixture
consisting of 5ul of standard plasmid or 5ul of CD14
positive DNA (10 ng/ul) made up to a volume of 9ul
with PCR grade water, together with 10ul of 2 × Taqman
Universal mastermix II with no UNG (Applied Biosystems)
and 1ul of FAM labeled CMV primer and probe were
loaded into a 96 well PCR plate (Eppendorf, Hamburg,
Germany). PCR amplification consisted of 2 min at 95 °C,
prior to 50 cycles at 95 °C for 10 s and 60 s at 60 °C. A
positive and negative control plus water well were included
in each experiment and the standard curve repeated in
triplicate and averaged. Samples were only considered
positive if present in triplicate.
Enzyme-linked immunosorbent assay (ELISA) testing for
CMV IgG titre
As described by Kilgour et al, CMV ELISA testing
(University of Birmingham, Birmingham UK) was used to
ascertain participant’s CMV status. Briefly, mock and viral
lysate were used to coat 95 well plate overnight at 4 °C.
Using plasma from 3 CMV positive donors, a standard
was prepared and added to the plate in a 1 in 4 serial
dilution, alongside 1ul of healthy donor samples. After 1 h
incubation at room temperature, the plate was washed
and anti-IgG horseradish peroxidase conjugated second-
ary antibody (Southern Biotech, Alabama, USA) added to
each well and incubated for a further 1 h in the dark, RT.
After repeat wash steps, 100 μL of TMB ELISA peroxidase
substrate (Rockland Immunochemicals, Pennsylvania,
USA) was added and incubated for 10 min in the dark,
RT. To stop the reaction, 100 μL of 1 mM HCl was added,
prior to reading on an ELISA plate reader at 450 nm [44].
CMV functionality testing
106 PBMC were resuspended in 500 ul RPMI plus 10 %
FCS and incubated with either 10 ul Peptivator EI-1, 10
ul Peptivator pp65 (Miltenyi Biotech, Bergisch Gladbach,
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Germany), 10 ul SEB (Sigma-Aldrich), or 10 ul RPMI.
0.5 ul of Brefeldin A was then added to all samples (Bio
Legend) and incubated over night at 37 °C in 5 % CO2.
Afterwards, cells were washed and stained with viability
dye-APC (Thermo Fisher Scientific) following manufac-
turer’s instructions. After two washes, surface staining
was performed, using anti-CD8 FITC, anti-CD4 PE-Cy7,
anti-CD3 APC-Cy7 (BDBiosciences). Cells were then
washed, fixed in 4 % paraformaldehyde (Sigma-Aldrich),
washed again, and permeabilized with 0.5 % saponin
(Sigma-Aldrich). After washing, cells were stained with
anti-IFNγ PE (Miltenyi Biotech), washed and analysed
using a FacsCanto II flow cytometer (BDBiosciences).
Statistical analysis
One way ANOVA (Kruskal-Wallis test) and post hoc
Dunn’s testing was used to compare CMV viral load with
age. A growth exponential curve was used to assess the
CMV load doubling time and linear regression used to
assess the relationship between CMV copies (log10) and
the age of participants. For the standard dilution series
ran in triplicate, the results were log transformed log10
and Pearson’s correlation co-efficient was used to com-
pare the quantitative agreement between ct value and
plasmid copy number. Linear regression was used to
examine the relationship between ddPCR copy number
reading and that of the plasmid dilution and also to
compare Q-PCR copy number with that of ddPCR in
healthy donor samples. Pearson’s correlation co-efficient
was used to examine the relationship between CMV IgG
titre and age. For comparison of age against functional T
cell responses against Spearman’s correlation co-efficient
was used. Mann-Whitney testing was used to compare
IFN-y responses in T cells following peptide stimulation
in those with detectable viral load compared to those
without. All analysis was performed using Prism version
6.0, Graphpad software, San Diego, USA.
Additional file
Additional file 1: Figure S1. A comparison of droplet digital PCR and
QPCR for CMV viral load. (A): Classic quantitative PCR (Q-PCR) was calibrated
using a series dilution of plasmid standards for CMV. The Ct value was
correlated with copy number in each dilution. (B): The serially diluted
standard plasmids were then assessed by ddPCR and the absolute copy
number obtained was correlated with the expected CMV copy number. (C):
Q-PCR was used to assess CMV load within the 44 samples of monocyte
DNA from healthy donors. The CMV copy number of the 13 donors that
were positive by both methods (Q-PCR and ddPCR) were then correlated.
(PDF 381 kb)
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